I-Ruxolitinib iyi-molecule encane i-Janus kinase inhibitor esetshenziswa ekwelapheni i-myelofibrosis eyingozi emaphakathi noma ephezulu kanye nezinhlobo ezimelana ne-polycythemia vera kanye nesifo se-graft-vs-host. I-Ruxolitinib ihlotshaniswa nokuphakama kwesikhashana futhi ngokuvamile okumaphakathi ku-serum aminotransferase phakathi nokwelashwa kanye nasezimweni ezingavamile zokulimala okunamandla kwesibindi okulinganiselwe, okubonakala ngokomtholampilo kanye nasezimweni zokuvuselela i-hepatitis B kubantu abathintekayo.

I-Ruxolitinib iyi-olly bioavailable Janus-associated kinase (JAK) inhibitor enemisebenzi engaba khona ye-antineoplastic kanye ne-immunomodulating. I-Ruxolitinib ibopha ngokuqondile futhi ivimbele amaprothenii-tyrosinekinases JAK 1 no-2, okungase kuholele ekunciphiseni ukuvuvukala kanye nokuvimbela ukwanda kwamaselula. Indlela ye-JAK-STAT (i-transducer yesiginali kanye ne-activator of transcription) idlala indima ebalulekile ekuboniseni ama-cytokines amaningi kanye nezici zokukhula futhi ihileleke ekwandeni kwamaselula, ukukhula, i-hematopoiesis, kanye nokusabela komzimba; I-JAK kinases ingase ilawuleke ezifweni ezivuthayo, izifo ze-myeloproliferative, kanye nezifo ezihlukahlukene.

I-Ruxolitinib ai-pyrazoleifakwe esikhundleni se-1 yiqembu le-2-cyano-1-cyclopentylethyl futhi endaweni yesi-3 yiqembu le-pyrrolo[2,3-d]pyrimidin-4-yl. Isetshenziswa njengosawoti we-phosphate ekwelapheni iziguli ezine-myelofibrosis emaphakathi noma engcuphe kakhulu, okuhlanganisa i-myelofibrosis eyinhloko, i-post-polycythemia vera myelofibrosis kanye ne-post-essential thrombocythemia myelofibrosis. Inendima njenge-ejenti ye-antineoplastic kanye ne-EC 2.7.10.2 (amaprotheni angaqondile-i-tyrosinekinase) inhibitor. I-nitrile, apyrrolopyrimidinekanye nelungu le-pyrazoles.